Topotecan, a topoisomerase I inhibitor, was evaluated in a multicenter, phase II study of women with epithelial ovarian carcinoma who relapsed after one or two prior regimens that included platinum and paclitaxel.
Bookman, M.A., Malmström, H., Bolis, G., Gordon, A., Lissoni, A., Krebs, J.B., et al. (1998). Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. JOURNAL OF CLINICAL ONCOLOGY, 16(10), 3345-3352.
Citazione: | Bookman, M.A., Malmström, H., Bolis, G., Gordon, A., Lissoni, A., Krebs, J.B., et al. (1998). Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. JOURNAL OF CLINICAL ONCOLOGY, 16(10), 3345-3352. |
Tipo: | Articolo in rivista - Articolo scientifico |
Carattere della pubblicazione: | Scientifica |
Titolo: | Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel |
Autori: | Bookman, MA; Malmström, H; Bolis, G; Gordon, A; Lissoni, A; Krebs, JB; Fields, SZ |
Autori: | |
Data di pubblicazione: | ott-1998 |
Lingua: | English |
Rivista: | JOURNAL OF CLINICAL ONCOLOGY |
Appare nelle tipologie: | 01 - Articolo su rivista |
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.